Zhalong National Nature Reserve （Zhalong） is an important stopover for migratory birds. In recent decades, Zhalong has become the focus of researchers and public discussion in relation to irrigation. We studied rela...Zhalong National Nature Reserve （Zhalong） is an important stopover for migratory birds. In recent decades, Zhalong has become the focus of researchers and public discussion in relation to irrigation. We studied relationships between birds and habitats at different water levels to guide development of more effective habitat management measures. We used line transects to survey bird numbers and distribution during April-May from 2005-2009 at Zhalong, and used cluster analysis and Chi-Square tests to analyze data. We recorded 139 bird species of 39 families and 13 orders during spring migration, including Anseriformes, Charadriiformes, Ciconiiformes, Columbiformes, Coraciiformes, Cucu- liformes, Falconiformes, Galliformes, Gruiformes, Passeriformes, Pici- formes, Podicipediformes, Strigiformes. Dominant vegetation and geo- graphic region were the main influence factors of avian distribution. Different ecological groups preferred different water levels （p〈0.01） and different habitat types （p〈0.01）. Grallatores, Natatores and Passeres were the main ecological groups in different wetland habitats, and reed marsh and lake are the main habitats for management. Grallatores preferred reed marsh and lake with water levels 〉30 cm and 5-15 cm. Natatores preferred lakes with deep water （〉30 cm）. Passeres preferred open forest and reed marsh with no surface water. Different avian ecological groups occupied specific habitats depending on water level and we recorded some overlaps in bird distribution.展开更多
Objective:To assess the effect and safety of Hydroxysafflor Yellow A for Injection(HSYAI)in treating patients with acute ischemic stroke(AIS)and blood stasis syndrome(BSS).Methods:A multicenter,randomized,double-blind...Objective:To assess the effect and safety of Hydroxysafflor Yellow A for Injection(HSYAI)in treating patients with acute ischemic stroke(AIS)and blood stasis syndrome(BSS).Methods:A multicenter,randomized,double-blind,multiple-dose,active-controlled phaseⅡtrial was conducted at 9 centers in China from July 2013 to September 2015.Patients with moderate or severe AIS and BSS were randomly assigned to low-,medium-,high-dose HSYAI groups(25,50 and 70 mg/d HSYAI by intravenous infusion,respectively),and a control group(Dengzhan Xixin Injection(灯盏细辛注射液,DZXXI)30 mL/d by intravenous infusion),for 14 consecutive days.The primary outcome was the Modified Rankin Scale(mRS)score 1 at days 90 after treatment.The secondary outcomes included the National Institute of Health Stroke Scale(NIHSS)score 1,Barthel Index(BI)score 95,and BSS score reduced 30%from baseline at days 14,30,60,and 90 after treatment.The safety outcomes included any adverse events during 90 days after treatment.Results:Of the 266 patients included in the effectiveness analysis,66,67,65 and 68 cases were in the low-,medium-,and high-dose HSYAI and control groups,respectively.The proportions of patients in the medium-and high-dose HSYAI groups with mRS score 1 at days 90 after treatment were significantly larger than the control group(P<0.05).The incidences of favorable outcomes of NIHSS and BI at days 90 after treatment as well as satisfactory improvement of BSS at days 30 and 60 after treatment in the medium-and high-dose HSYAI groups were all significantly higher than the control group(P<0.05).No significant difference was reported among the 4 groups in any specific adverse events(P>0.05).Conclusions:HSYAI was safe and well-tolerated at all doses for treating AIS patients with BSS.The medium(50 mg/d)or high dose(75 mg/d)might be the optimal dose for a phaseⅢtrial.展开更多
基金supported by the Fundamental Research Funds for the Central Universities (No. DL12EA04 and DL11BA01)National Natural Science Foundation of China (No.31070345 and 30670350)+1 种基金China Postdoctoral Science Foundation (No.2011M500631)Heilongjiang Postdoctoral Foundation (No.520-415268)
文摘Zhalong National Nature Reserve （Zhalong） is an important stopover for migratory birds. In recent decades, Zhalong has become the focus of researchers and public discussion in relation to irrigation. We studied relationships between birds and habitats at different water levels to guide development of more effective habitat management measures. We used line transects to survey bird numbers and distribution during April-May from 2005-2009 at Zhalong, and used cluster analysis and Chi-Square tests to analyze data. We recorded 139 bird species of 39 families and 13 orders during spring migration, including Anseriformes, Charadriiformes, Ciconiiformes, Columbiformes, Coraciiformes, Cucu- liformes, Falconiformes, Galliformes, Gruiformes, Passeriformes, Pici- formes, Podicipediformes, Strigiformes. Dominant vegetation and geo- graphic region were the main influence factors of avian distribution. Different ecological groups preferred different water levels （p〈0.01） and different habitat types （p〈0.01）. Grallatores, Natatores and Passeres were the main ecological groups in different wetland habitats, and reed marsh and lake are the main habitats for management. Grallatores preferred reed marsh and lake with water levels 〉30 cm and 5-15 cm. Natatores preferred lakes with deep water （〉30 cm）. Passeres preferred open forest and reed marsh with no surface water. Different avian ecological groups occupied specific habitats depending on water level and we recorded some overlaps in bird distribution.
文摘Objective:To assess the effect and safety of Hydroxysafflor Yellow A for Injection(HSYAI)in treating patients with acute ischemic stroke(AIS)and blood stasis syndrome(BSS).Methods:A multicenter,randomized,double-blind,multiple-dose,active-controlled phaseⅡtrial was conducted at 9 centers in China from July 2013 to September 2015.Patients with moderate or severe AIS and BSS were randomly assigned to low-,medium-,high-dose HSYAI groups(25,50 and 70 mg/d HSYAI by intravenous infusion,respectively),and a control group(Dengzhan Xixin Injection(灯盏细辛注射液,DZXXI)30 mL/d by intravenous infusion),for 14 consecutive days.The primary outcome was the Modified Rankin Scale(mRS)score 1 at days 90 after treatment.The secondary outcomes included the National Institute of Health Stroke Scale(NIHSS)score 1,Barthel Index(BI)score 95,and BSS score reduced 30%from baseline at days 14,30,60,and 90 after treatment.The safety outcomes included any adverse events during 90 days after treatment.Results:Of the 266 patients included in the effectiveness analysis,66,67,65 and 68 cases were in the low-,medium-,and high-dose HSYAI and control groups,respectively.The proportions of patients in the medium-and high-dose HSYAI groups with mRS score 1 at days 90 after treatment were significantly larger than the control group(P<0.05).The incidences of favorable outcomes of NIHSS and BI at days 90 after treatment as well as satisfactory improvement of BSS at days 30 and 60 after treatment in the medium-and high-dose HSYAI groups were all significantly higher than the control group(P<0.05).No significant difference was reported among the 4 groups in any specific adverse events(P>0.05).Conclusions:HSYAI was safe and well-tolerated at all doses for treating AIS patients with BSS.The medium(50 mg/d)or high dose(75 mg/d)might be the optimal dose for a phaseⅢtrial.
